Philips spin off Hemics secured funding via health care provider De Friesland and its investment fund DFZ Participaties.The startup develops a device that can track symptoms of rheumatism in human joints.
Hemics’ HandScan may be further developed with the money – of which the exact amount was not disclosed. Together with the new funds of previous investors Thuja Capital, Point One Innovation Fund and the Brabantse Ontwikkelingsmaatschappij (BOM), “several millions of euro’s ” were secured according to Hemics.
“The involvement and trust of De Friesland insurer is very important”, says co-founder Petra van den Elsen. “Because the use of our system is not yet covered in an insurance policy.” The benefits of the HandScan first have to be proven, but research in this area is expensive.
Hemics’ system makes sure that patient can be scanned for rheumatism within minutes and without the use of pressure that may hurt the person. Normally doctors would for example have to squeeze the hand of the patient in order to diagnose the problem. “Painful and subjective”, explains Van den Elsen.
DFZ Participaties expects the HandScan will bring down the costs of care, because it will be easier and quicker to examine patients and diagnose the disease. The first systems are already in use by hospital UMC Utrecht. “We also recently received the CE quality mark that is needed to sell this kind of product”, says Van den Elsen.
Photo provided by Hemics